499 related articles for article (PubMed ID: 27720295)
1. Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
Abdeen S; Salim N; Mammadova N; Summers CM; Goldsmith-Pestana K; McMahon-Pratt D; Schultz PG; Horwich AL; Chapman E; Johnson SM
Bioorg Med Chem Lett; 2016 Nov; 26(21):5247-5253. PubMed ID: 27720295
[TBL] [Abstract][Full Text] [Related]
2. HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
Stevens M; Abdeen S; Salim N; Ray AM; Washburn A; Chitre S; Sivinski J; Park Y; Hoang QQ; Chapman E; Johnson SM
Bioorg Med Chem Lett; 2019 May; 29(9):1106-1112. PubMed ID: 30852084
[TBL] [Abstract][Full Text] [Related]
3. GroEL/ES inhibitors as potential antibiotics.
Abdeen S; Salim N; Mammadova N; Summers CM; Frankson R; Ambrose AJ; Anderson GG; Schultz PG; Horwich AL; Chapman E; Johnson SM
Bioorg Med Chem Lett; 2016 Jul; 26(13):3127-3134. PubMed ID: 27184767
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapeutic strategies against Trypanosoma brucei: drug targets vs. drug targeting.
Lüscher A; de Koning HP; Mäser P
Curr Pharm Des; 2007; 13(6):555-67. PubMed ID: 17346174
[TBL] [Abstract][Full Text] [Related]
5. Treatment of African trypanosomiasis with cordycepin and adenosine deaminase inhibitors in a mouse model.
Rottenberg ME; Masocha W; Ferella M; Petitto-Assis F; Goto H; Kristensson K; McCaffrey R; Wigzell H
J Infect Dis; 2005 Nov; 192(9):1658-65. PubMed ID: 16206083
[TBL] [Abstract][Full Text] [Related]
6. Development of novel drugs for human African trypanosomiasis.
Brun R; Don R; Jacobs RT; Wang MZ; Barrett MP
Future Microbiol; 2011 Jun; 6(6):677-91. PubMed ID: 21707314
[TBL] [Abstract][Full Text] [Related]
7. Parasite Polyamines as Pharmaceutical Targets.
Roberts S; Ullman B
Curr Pharm Des; 2017; 23(23):3325-3341. PubMed ID: 28571553
[TBL] [Abstract][Full Text] [Related]
8. Sleeping sickness pathogen (Trypanosoma brucei) and natural products: therapeutic targets and screening systems.
Hannaert V
Planta Med; 2011 Apr; 77(6):586-97. PubMed ID: 20945274
[TBL] [Abstract][Full Text] [Related]
9. 2-(Nitroaryl)-5-Substituted-1,3,4-Thiadiazole Derivatives with Antiprotozoal Activities: In Vitro and In Vivo Study.
Mousavi A; Foroumadi P; Emamgholipour Z; Mäser P; Kaiser M; Foroumadi A
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080325
[TBL] [Abstract][Full Text] [Related]
10. Flavonoid-derived Privileged Scaffolds in anti-Trypanosoma brucei Drug Discovery.
Boniface PK; Elizabeth FI
Curr Drug Targets; 2019; 20(12):1295-1314. PubMed ID: 31215385
[TBL] [Abstract][Full Text] [Related]
11. Anti-trypanosomal activities of DNA topoisomerase inhibitors.
Deterding A; Dungey FA; Thompson KA; Steverding D
Acta Trop; 2005 Mar; 93(3):311-6. PubMed ID: 15715983
[TBL] [Abstract][Full Text] [Related]
12. Activity of Aromathecins against African Trypanosomes.
Nenortas NP; Cinelli MA; Morrell AE; Cushman M; Shapiro TA
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104277
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors.
Buchynskyy A; Gillespie JR; Hulverson MA; McQueen J; Creason SA; Ranade RM; Duster NA; Gelb MH; Buckner FS
Bioorg Med Chem; 2017 Mar; 25(5):1571-1584. PubMed ID: 28187957
[TBL] [Abstract][Full Text] [Related]
14. Exploiting the HSP60/10 chaperonin system as a chemotherapeutic target for colorectal cancer.
Ray AM; Salim N; Stevens M; Chitre S; Abdeen S; Washburn A; Sivinski J; O'Hagan HM; Chapman E; Johnson SM
Bioorg Med Chem; 2021 Jun; 40():116129. PubMed ID: 33971488
[TBL] [Abstract][Full Text] [Related]
15. Evaluating the impact of targeting livestock for the prevention of human and animal trypanosomiasis, at village level, in districts newly affected with T. b. rhodesiense in Uganda.
Hamill L; Picozzi K; Fyfe J; von Wissmann B; Wastling S; Wardrop N; Selby R; Acup CA; Bardosh KL; Muhanguzi D; Kabasa JD; Waiswa C; Welburn SC
Infect Dis Poverty; 2017 Feb; 6(1):16. PubMed ID: 28162093
[TBL] [Abstract][Full Text] [Related]
16. 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
Ferrins L; Rahmani R; Sykes ML; Jones AJ; Avery VM; Teston E; Almohaywi B; Yin J; Smith J; Hyland C; White KL; Ryan E; Campbell M; Charman SA; Kaiser M; Baell JB
Eur J Med Chem; 2013 Aug; 66():450-65. PubMed ID: 23831695
[TBL] [Abstract][Full Text] [Related]
17. Transporters of Trypanosoma brucei-phylogeny, physiology, pharmacology.
Schmidt RS; Macêdo JP; Steinmann ME; Salgado AG; Bütikofer P; Sigel E; Rentsch D; Mäser P
FEBS J; 2018 Mar; 285(6):1012-1023. PubMed ID: 29063677
[TBL] [Abstract][Full Text] [Related]
18. Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT.
Ciammaichella A; Ferrigno F; Basta A; D'Amico M; Biancofiore I; Nardi V; Ponzi S; Graziani R; Gennari N; Vittoria Orsale M; Fini I; Paonessa G; Summa V; Harper S; Ontoria JM
Bioorg Med Chem Lett; 2020 Jun; 30(12):127207. PubMed ID: 32354566
[TBL] [Abstract][Full Text] [Related]
19. 2,4-Diaminopyrimidines as potent inhibitors of Trypanosoma brucei and identification of molecular targets by a chemical proteomics approach.
Mercer L; Bowling T; Perales J; Freeman J; Nguyen T; Bacchi C; Yarlett N; Don R; Jacobs R; Nare B
PLoS Negl Trop Dis; 2011 Feb; 5(2):e956. PubMed ID: 21347454
[TBL] [Abstract][Full Text] [Related]
20. Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.
Engel JA; Jones AJ; Avery VM; Sumanadasa SD; Ng SS; Fairlie DP; Skinner-Adams T; Andrews KT
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):117-26. PubMed ID: 26199860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
